ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "methotrexate (MTX)"

  • Abstract Number: 1236 • 2019 ACR/ARP Annual Meeting

    Subcutaneous or Oral Methotrexate Exposure and Response to Pegloticase in Uncontrolled Gout Patients in a Community Rheumatology Practice

    John A. Albert1, Tony Hosey 2 and Brian LaMoreaux 2, 1Rheumatic Disease Center, Milwaukee, IL, 2Horizon Therapeutics plc, Lake Forest, IL

    Background/Purpose: Pegloticase is an infused biologic for uncontrolled gout patients that is highly effective but can cause anti-drug antibodies that lead to a lack of…
  • Abstract Number: 2386 • 2019 ACR/ARP Annual Meeting

    Consensus Statement and Recommendations on Methotrexate Use in Combined Therapy with Biological or Targeted Synthetic Disease Modifying Drugs in Patients with Rheumatoid Arthritis

    Jesus Tornero1, Mercedes Alperi-López 2, Ivan Castellvi 3, Juan José de Agustín de Oro 4, Alejandro Escudero 5, Rosario Garcia-Vicuña 6, Miguel Angel González-Gay 7, Cristina Hidalgo 8, Esteban Rubio 9, Raimon Sanmarti 10, Núria Casamira 11 and Jaime Calvo-Alen 12, 1Hospital de Guadalajara, Guadalajara, Spain, 2Hospital Universitario Central de Asturias, Oviedo, Spain, 3Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 4Hospital Universitari Vall d’Hebron, Barcelona, Spain, 5IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, 6Hospital Universitario de La Princesa, Madrid, Spain, 7Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 8Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, 9Rheumatology Department, University Hospital Virgen del Rocío, Sevilla, Spain, 10Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, 11Medical Department, Gebro Pharma S.A., Barcelona, Spain, 12Hospital Universitario Araba, Vitoria-Gasteiz, Spain

    Background/Purpose: Our aim was to develop recommendations for the management of methotrexate (MTX) when considering the combination with biological (b) or targeted synthetic (ts) disease…
  • Abstract Number: 1279 • 2019 ACR/ARP Annual Meeting

    Response Rate and Sustained Remission in Idiopathic Inflammatory Myopathies Receiving Conventional Immunosuppressive Stepwise Management

    Alain Sánchez-Rodríguez1, Citlallyc Josefina Gómez-Ruiz 2, Abril Montes-Yanes 2 and Gabriel Medrano-Ramírez 2, 1Hospital General de Mexico, Mexico City, Distrito Federal, Mexico, 2Hospital General de Mexico, Rheumatology Department, Ciudad de Mexico, Distrito Federal, Mexico

    Background/Purpose: Information regarding response rate and sustained remission in patients with idiopathic inflammatory myopathies (IIM), polymyositis (PM), dermatomyositis (DM), in Hispanics with non-biological treatment is…
  • Abstract Number: 2394 • 2019 ACR/ARP Annual Meeting

    Use and Influence of Biologic/Janus Kinase Monotherapy Among Recently Switched Rheumatoid Arthritis Patients: Results from an Annual National Patient Chart Audit

    Lynn Price1, Phil Pouliot 1 and Lauren Schmitt 1, 1Spherix Global Insights, Exton, PA

    Background/Purpose: US rheumatologists have long agreed that methotrexate (MTX) is the backbone of rheumatoid arthritis (RA) treatment, and while comfort with biologic/JAK monotherapy is growing,…
  • Abstract Number: 1338 • 2019 ACR/ARP Annual Meeting

    Joint-specific Responses to Tofacitinib and Methotrexate in Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Start

    Mojca Frank-Bertoncelj1, Oliver Distler 2, Tim Killeen 3, Kenneth Kwok 4, Lisy Wang 5, Caroline Ospelt 1 and Adrian Ciurea 1, 1University Hospital Zürich, Zürich, Switzerland, 2Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, 3Pfizer AG, Zürich, Switzerland, 4Pfizer Inc, New York, NY, 5Pfizer Inc, Groton, CT

    Background/Purpose: Despite systemic inflammatory cues, RA affects synovial joints variably. Tofacitinib is an oral JAK inhibitor for the treatment of RA. Previous post hoc analyses…
  • Abstract Number: 2401 • 2019 ACR/ARP Annual Meeting

    Enhanced Methotrexate Polyglutamation in Japanese as Compared to Caucasian Rheumatoid Arthritis Patients Starting Methotrexate

    Thierry Dervieux1, Joel Kremer 2, Kelley Brady 1, Chihiro Takahashi 3, Tsutomu Takeuchi 4 and Yuko Kaneko 5, 1Exagen, Vista, CA, 2Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY, 3Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, 4Keio University Hospital Division of Rheumatology, Tokyo, Japan, 5Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku, Tokyo, Japan

    Background/Purpose: Methotrexate (MTX) is an anti-folate prodrug activated to MTX polyglutamates (MTXPGs). Japanese Rheumatoid Arthritis (RA) patients are thought to have heightened sensitivity to MTX…
  • Abstract Number: 1436 • 2019 ACR/ARP Annual Meeting

    Analysis of Adverse Events of Methotrexate (MTX), bDMARDs and Tofacitinib (TOFA) Reported to Pharmaceuticals and Medical Devices Agency (PMDA), Japan

    Naonori Tsuda1, Shigeko Inokuma 2, Kenichi Hiraga 3, Yoshinori Masui 3 and Toshikazu Kano 3, 1Kohondai Hospital, National Center for Global health and Medicine, Ichikawa, Chiba, Japan, 2Chiba Central Medical Center, Ichikawa, Chiba, Japan, 3Kohnodai Hospital, National Center for Global health and Medicine, Ichikawa, Chiba, Japan

    Background/Purpose: Among DMARDs (disease modifying anti-rheumatic drugs), methotrexate (MTX), bDMARDs (biologic DMARDs) and JAK (Janus kinase) inhibitors are the major. Many adverse events of these…
  • Abstract Number: 2404 • 2019 ACR/ARP Annual Meeting

    Does Combined Therapy Affects Adherence in Rheumatoid Arthritis?

    Iván de Jesús Hernández-Galarza 1, Rita Pineda-Sic1, Marielva Castro-Gonzalez 1, Diana Elsa Flores-Alvarado 1, Octavio Ilizaliturri-Guerra 1, Rodolfo Uriarte-Botello 1 and Dionicio Galarza-Delgado 1, 1Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr Jose Eleuterio Gonzalez", Monterrey, Nuevo Leon, Mexico

    Background/Purpose: Treatment adherence in Rheumatoid Arthritis (RA) patients vary from 30 to 80%. It is important to identify the associated factors to a low adherence,…
  • Abstract Number: 1441 • 2019 ACR/ARP Annual Meeting

    Is Background Methotrexate Still Advantageous in Extending TNF Drug Survival in the Elderly: An Analysis of the British Society for Rheumatology Biologics Register – Rheumatoid Arthritis

    Katie Bechman1, Anuoluwapo Oke 2, Mark Yates 3, Sam Norton 3, Elaine Denderson 4, Andrew Cope 5 and James Galloway 2, 1Kings College London, London, England, United Kingdom, 2Kings College London, London, United Kingdom, 3Kings College London, London, 4MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, 5Academic Rheumatology, King's College London, London, United Kingdom

    Background/Purpose: Long-term observational data from national registries in rheumatoid arthritis allow the examination of TNF drug survival rates. Despite a good initial response to a…
  • Abstract Number: 2476 • 2019 ACR/ARP Annual Meeting

    Side Effects of Methotrexate and TNFi: Differences in Tolerability Among Patients with PsA and RA

    Alexis Ogdie1, Ervant Maksabedian 2, Bradley Stolshek 2, Yomei Shaw 3 and Kaleb Michaud 4, 1University of Pennsylvania, Philadelphia, PA, 2Amgen Inc., Thousand Oaks, CA, 3FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, 4FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS

    Background/Purpose: Methotrexate (MTX) is generally well tolerated in rheumatoid arthritis (RA) but little is known about the tolerability of MTX in psoriatic arthritis (PsA).  One…
  • Abstract Number: 1533 • 2019 ACR/ARP Annual Meeting

    The Performance Characteristics of Composite Measures Used in a Randomized Trial Examining Etanercept and Methotrexate as Monotherapy or in Combination in Patients with Psoriatic Arthritis

    Laura Coates1, Joseph Merola 2, Philip Mease 3, Alexis Ogdie 4, Dafna Gladman 5, Vibeke Strand 6, Leonieke van Mens 7, Lyrica Liu 8, Priscilla K Yen 8, David Collier 8, Gregory Kricorian 8, James Chung 8 and Philip Helliwell 9, 1University of Oxford, Oxford, United Kingdom, 2Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, 3Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, 4Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 5Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, 6Division of Immunology/Rheumatology, Stanford University, Stanford, CA, 7University of Amsterdam, Amsterdam, Netherlands, 8Amgen Inc., Thousand Oaks, CA, 9University of Leeds, Leeds, United Kingdom

    Background/Purpose: Composite measures of disease activity are used in psoriatic arthritis (PsA), but their relative performance and contributions of individual components to overall scores are…
  • Abstract Number: 2860 • 2019 ACR/ARP Annual Meeting

    Perturbation of the Human Gut Microbiome by Methotrexate Contributes to the Resolution of Inflammation and Autoimmune Disease

    Renuka Nayak1, Margaret Alexander 1, Kye Stapleton-Grey 2, Carles Ubeda 3, Jose Scher 4 and Peter Turnbaugh 1, 1UCSF, San Francisco, 2Carnegie Mellon, Pittsburg, 3Centro Superior de Investigación en Salud Pública - FISABIO, Valencia, Spain, 4Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY

    Background/Purpose: The trillions of microorganisms (microbiota) found within the human gut play a critical role in shaping the immune system, yet these complex microbial communities…
  • Abstract Number: 1759 • 2019 ACR/ARP Annual Meeting

    Methotrexate in Patients with Hand Erosive Osteoarthritis Refractory to Usual Treatments: A Randomized, Double-blind, Placebo-controlled Trial

    stéphanie Ferrero 1, Ruth Wittoek 2, Edem Allado 3, Coralie Cruzel 4, Véronique Breuil 1, Liana Euller Ziegler 5, Damien louille 6, Christian Roux7 and Joel Kremer 8, 1University of Nice, nice, France, 2Ghent University Hospital, Gent University, Gent, Belgium, 3Centre Hospitalier Universitaire de Nancy, Nancy, France, 4Université Cote d'Azur, nice, France, 5PUPH CHU NICE, nice, France, 6Université Cote d'Azur, Nancy, France, 7Université Cote d'Azur, Nice, 8Albany Medical College, Albany, NY

    Background/Purpose: No studies have assessed the effect of methotrexate (MTX) in osteoarthritis of the hand (HOA). The purpose of our study was to examine the…
  • Abstract Number: L06 • 2018 ACR/ARHP Annual Meeting

    Safety and Efficacy of Filgotinib in a Phase 3 Trial of Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic Dmards

    Mark C. Genovese1, Kenneth C. Kalunian2, David Walker3, Jacques-Eric Gottenberg4, Kurt de Vlam5, Neelufar Mozaffarian6, Beatrix Bartok6, Franziska Matzkies6, Jie Gao6, Ying Guo6, Chantal Tasset7, John S. Sundy6 and Tsutomu Takeuchi8, 1Division of Immunology & Rheumatology, Stanford University, Stanford, CA, 2Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, 3Northumbria Healthcare, United Kingdom, United Kingdom, 4Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 5Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, 6Gilead Sciences, Inc., Foster City, CA, 7Galapagos NV, Mechelen, Belgium, Mechelen, Belgium, 8Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: Filgotinib (FIL), an oral, selective, Janus Kinase 1 (JAK1) inhibitor was effective in phase 2 studies of active RA in patients (pts) with insufficient…
  • Abstract Number: L11 • 2018 ACR/ARHP Annual Meeting

    Etanercept and Methotrexate As Monotherapy or in Combination in Patients with Psoriatic Arthritis: A Phase 3, Double-Blind, Randomized Controlled Study

    Philip J. Mease1, Dafna D. Gladman2, David H. Collier3, Christopher T. Ritchlin4, Philip S. Helliwell5, Lyrica Liu6, Gregory J. Kricorian3 and James B. Chung3, 1Swedish Medical Center and University of Washington, Seattle, WA, 2University of Toronto, Toronto, ON, Canada, 3Amgen Inc., Thousand Oaks, CA, 4University of Rochester Medical Center, Rochester, NY, 5University of Leeds, Leeds, United Kingdom, 6Amgen Inc., South San Francisco, CA

    Background/Purpose:  Methotrexate (MTX) and tumor necrosis factor inhibitors (TNFi) such as etanercept (ETN) are often prescribed for psoriatic arthritis (PsA) either alone or in combination,…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 16
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology